

CONFIDENTIAL
PROPOSED CLAIMS
FOR DISCUSSION PURPOSES ONLY

21. A pharmaceutical composition useful for treating Galactosialidosis comprising protective protein/cathepsin A (PPCA) and a pharmaceutically acceptable carrier, wherein said PPCA is produced in an insect cell culture and has a unique glycosylation pattern that includes exposed mannose residues. *comprises*
22. The composition of claim 21 wherein said insect cell culture comprises cells derived from the species selected from the group consisting of *Spodoptera frugiperda* and *Tricoplusia ni*.
23. The composition of claim 22 wherein said cells are *Spodoptera frugiperda* Sf9 cells.
24. The composition of claim 21 wherein said PPCA is produced in the insect cell culture using a baculovirus expression system.

Proposed claim 21 incorporates limitations suggested in the July 1 Office Action. Support for the limitation regarding the unique glycosylation pattern and exposed mannose residues can be found at page 14, lines 7-8 of the specification. Other limitations appear in existing claims.

Proposed dependent claims 22-24 correspond to pending claims 11-13.

? cancel the claims &
non-elected claims